Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study
BackgroundManagement of patients with cancer in the current era of the COVID-19 pandemic poses a significant challenge to health care systems. Breast cancer is the most common cancer internationally. Breast cancer is a disease that involves surgery, chemotherapy, hormonal the...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2021-11-01
|
| Series: | JMIR Cancer |
| Online Access: | https://cancer.jmir.org/2021/4/e27073 |
| _version_ | 1797735546939768832 |
|---|---|
| author | Shereef Elsamany Mohamed Elbaiomy Ahmed Zeeneldin Emad Tashkandi Fayza Hassanin Nafisa Abdelhafeez Humaid O Al-Shamsi Nedal Bukhari Omima Elemam |
| author_facet | Shereef Elsamany Mohamed Elbaiomy Ahmed Zeeneldin Emad Tashkandi Fayza Hassanin Nafisa Abdelhafeez Humaid O Al-Shamsi Nedal Bukhari Omima Elemam |
| author_sort | Shereef Elsamany |
| collection | DOAJ |
| description |
BackgroundManagement of patients with cancer in the current era of the COVID-19 pandemic poses a significant challenge to health care systems. Breast cancer is the most common cancer internationally. Breast cancer is a disease that involves surgery, chemotherapy, hormonal therapy, targeted therapy, radiotherapy, and, more recently, immunotherapy in its management plan. The immune system requires months to recover from these medications, and this condition is even worse in patients with metastatic breast cancer who need ongoing treatment with these drugs. Some of these drugs, such as inhibitors of cyclin-dependent kinases 4 and 6, can cause rare but life-threating lung inflammation. Patients with breast cancer who have metastatic disease to the lungs can experience deterioration of disease symptoms with COVID-19 infection. Oncologists treating patients with breast cancer are facing a difficult situation regarding treatment choice. The impact that COVID-19 has had on breast cancer care is unknown, including how to provide the best care possible without compromising patient and community safety.
ObjectiveThe aim of this study was to explore the views of oncologists regarding the management of patients with breast cancer during the COVID-19 pandemic.
MethodsA web-based SurveyMonkey questionnaire was submitted to licensed oncologists involved in breast cancer management in Saudi Arabia, Egypt, and United Arab Emirates. The survey focused on characteristics of the participants, infection risk among patients with cancer, and possible treatment modifications related to different types of breast cancer.
ResultsThe survey was completed by 82 participants. For early hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer, 61 of the 82 participants (74%) supported using neoadjuvant hormonal therapy in selected patients, and 58% (48/82) preferred giving 6 over 8 cycles of adjuvant chemotherapy when indicated. Only 43% (35/82) preferred inhibitors of cyclin-dependent kinases 4 and 6 with hormonal therapy as the first-line treatment in all patients with metastatic HR-positive disease. A total of 55 of the 82 participants (67%) supported using adjuvant trastuzumab for 6 instead of 12 months in selected patients with HER2-positive breast cancer. For metastatic HER2-positive, HR-positive breast cancer, 80% of participants (66/82) supported the use of hormonal therapy with dual anti-HER2 blockade in selected patients. The preferred choice of first-line treatment in metastatic triple negative patients with BRCA mutation and programmed cell death 1 ligand 1 (PD-L1) <1% was poly(adenosine diphosphate–ribose) polymerase inhibitor according to 41% (34/82) of the participants, and atezolizumab with nab-paclitaxel was preferred for PD-L1 >1% according to 71% (58/82) of the participants.
ConclusionsSeveral modifications in breast cancer management were supported by the survey participants. These modifications need to be discussed on a local basis, taking into account the local infrastructure and available resources. |
| first_indexed | 2024-03-12T13:00:40Z |
| format | Article |
| id | doaj.art-a0196199bd1a45c19a0765b2ed81f79a |
| institution | Directory Open Access Journal |
| issn | 2369-1999 |
| language | English |
| last_indexed | 2024-03-12T13:00:40Z |
| publishDate | 2021-11-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Cancer |
| spelling | doaj.art-a0196199bd1a45c19a0765b2ed81f79a2023-08-28T19:46:40ZengJMIR PublicationsJMIR Cancer2369-19992021-11-0174e2707310.2196/27073Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey StudyShereef Elsamanyhttps://orcid.org/0000-0001-5506-6494Mohamed Elbaiomyhttps://orcid.org/0000-0001-8702-7633Ahmed Zeeneldinhttps://orcid.org/0000-0002-7284-4320Emad Tashkandihttps://orcid.org/0000-0002-0260-8947Fayza Hassaninhttps://orcid.org/0000-0002-7148-8678Nafisa Abdelhafeezhttps://orcid.org/0000-0003-4697-7688Humaid O Al-Shamsihttps://orcid.org/0000-0003-3819-0500Nedal Bukharihttps://orcid.org/0000-0002-6166-5490Omima Elemamhttps://orcid.org/0000-0003-1576-5877 BackgroundManagement of patients with cancer in the current era of the COVID-19 pandemic poses a significant challenge to health care systems. Breast cancer is the most common cancer internationally. Breast cancer is a disease that involves surgery, chemotherapy, hormonal therapy, targeted therapy, radiotherapy, and, more recently, immunotherapy in its management plan. The immune system requires months to recover from these medications, and this condition is even worse in patients with metastatic breast cancer who need ongoing treatment with these drugs. Some of these drugs, such as inhibitors of cyclin-dependent kinases 4 and 6, can cause rare but life-threating lung inflammation. Patients with breast cancer who have metastatic disease to the lungs can experience deterioration of disease symptoms with COVID-19 infection. Oncologists treating patients with breast cancer are facing a difficult situation regarding treatment choice. The impact that COVID-19 has had on breast cancer care is unknown, including how to provide the best care possible without compromising patient and community safety. ObjectiveThe aim of this study was to explore the views of oncologists regarding the management of patients with breast cancer during the COVID-19 pandemic. MethodsA web-based SurveyMonkey questionnaire was submitted to licensed oncologists involved in breast cancer management in Saudi Arabia, Egypt, and United Arab Emirates. The survey focused on characteristics of the participants, infection risk among patients with cancer, and possible treatment modifications related to different types of breast cancer. ResultsThe survey was completed by 82 participants. For early hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer, 61 of the 82 participants (74%) supported using neoadjuvant hormonal therapy in selected patients, and 58% (48/82) preferred giving 6 over 8 cycles of adjuvant chemotherapy when indicated. Only 43% (35/82) preferred inhibitors of cyclin-dependent kinases 4 and 6 with hormonal therapy as the first-line treatment in all patients with metastatic HR-positive disease. A total of 55 of the 82 participants (67%) supported using adjuvant trastuzumab for 6 instead of 12 months in selected patients with HER2-positive breast cancer. For metastatic HER2-positive, HR-positive breast cancer, 80% of participants (66/82) supported the use of hormonal therapy with dual anti-HER2 blockade in selected patients. The preferred choice of first-line treatment in metastatic triple negative patients with BRCA mutation and programmed cell death 1 ligand 1 (PD-L1) <1% was poly(adenosine diphosphate–ribose) polymerase inhibitor according to 41% (34/82) of the participants, and atezolizumab with nab-paclitaxel was preferred for PD-L1 >1% according to 71% (58/82) of the participants. ConclusionsSeveral modifications in breast cancer management were supported by the survey participants. These modifications need to be discussed on a local basis, taking into account the local infrastructure and available resources.https://cancer.jmir.org/2021/4/e27073 |
| spellingShingle | Shereef Elsamany Mohamed Elbaiomy Ahmed Zeeneldin Emad Tashkandi Fayza Hassanin Nafisa Abdelhafeez Humaid O Al-Shamsi Nedal Bukhari Omima Elemam Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study JMIR Cancer |
| title | Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study |
| title_full | Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study |
| title_fullStr | Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study |
| title_full_unstemmed | Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study |
| title_short | Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study |
| title_sort | suggested modifications to the management of patients with breast cancer during the covid 19 pandemic web based survey study |
| url | https://cancer.jmir.org/2021/4/e27073 |
| work_keys_str_mv | AT shereefelsamany suggestedmodificationstothemanagementofpatientswithbreastcancerduringthecovid19pandemicwebbasedsurveystudy AT mohamedelbaiomy suggestedmodificationstothemanagementofpatientswithbreastcancerduringthecovid19pandemicwebbasedsurveystudy AT ahmedzeeneldin suggestedmodificationstothemanagementofpatientswithbreastcancerduringthecovid19pandemicwebbasedsurveystudy AT emadtashkandi suggestedmodificationstothemanagementofpatientswithbreastcancerduringthecovid19pandemicwebbasedsurveystudy AT fayzahassanin suggestedmodificationstothemanagementofpatientswithbreastcancerduringthecovid19pandemicwebbasedsurveystudy AT nafisaabdelhafeez suggestedmodificationstothemanagementofpatientswithbreastcancerduringthecovid19pandemicwebbasedsurveystudy AT humaidoalshamsi suggestedmodificationstothemanagementofpatientswithbreastcancerduringthecovid19pandemicwebbasedsurveystudy AT nedalbukhari suggestedmodificationstothemanagementofpatientswithbreastcancerduringthecovid19pandemicwebbasedsurveystudy AT omimaelemam suggestedmodificationstothemanagementofpatientswithbreastcancerduringthecovid19pandemicwebbasedsurveystudy |